Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.

IF 1.7 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2023-01-01 DOI:10.1159/000529750

Mei Bao, Mengyu Zhang, Hongxia Shi, Xiaoli Liu, Minghui Duan, Junling Zhuang, Xin Du, Ling Qin, Wuhan Hui, Rong Liang, Meifang Wang, Ye Chen, Dongyun Li, Wei Yang, Gusheng Tang, Weihua Zhang, Xia Kuang, Wei Su, Yanqiu Han, Limei Chen, Jihong Xu, Zhuogang Liu, Jian Huang, Chunting Zhao, Hongyan Tong, Jianda Hu, Chunyan Chen, Xiequn Chen, Zhijian Xiao, Qian Jiang

{"title":"Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.","authors":"Mei Bao, Mengyu Zhang, Hongxia Shi, Xiaoli Liu, Minghui Duan, Junling Zhuang, Xin Du, Ling Qin, Wuhan Hui, Rong Liang, Meifang Wang, Ye Chen, Dongyun Li, Wei Yang, Gusheng Tang, Weihua Zhang, Xia Kuang, Wei Su, Yanqiu Han, Limei Chen, Jihong Xu, Zhuogang Liu, Jian Huang, Chunting Zhao, Hongyan Tong, Jianda Hu, Chunyan Chen, Xiequn Chen, Zhijian Xiao, Qian Jiang","doi":"10.1159/000529750","DOIUrl":null,"url":null,"abstract":"Introduction: Genetic landscape, disease characteristics, and clinical outcomes of young adults with myeloproliferative neoplasms (MPNs) were reported. However, data on patient-reported outcomes (PROs) in young adults with MPNs were rare.Methods: We conducted a multicenter, cross-sectional study to compare the PROs in respondents with thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) by age at survey, including the young group (18-40 years), middle-aged group (41-60 years), and elderly group (>60 years).Results: Of the 1,664 respondents with MPNs, 349 (21.0%) were young including 244 (69.9%) with ET, 34 (9.7%) with PV, and 71 (20.3%) with MF. In multivariate analyses, the young groups with ET and MF were associated with the lowest MPN-10 scores among the 3 age groups; those with MF, highest proportion of reporting negative impact of disease and therapy on their daily life and work. The young groups with MPNs had the highest physical component summary scores but the lowest mental component summary scores in those with ET. The young groups with MPNs were most concerned about fertility; those with ET, treatment-related adverse events and long-term efficacy of treatment.Conclusions: We concluded that young adults with MPNs have different PROs compared with middle-aged and elderly patients.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":"146 4","pages":"293-306"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000529750","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Genetic landscape, disease characteristics, and clinical outcomes of young adults with myeloproliferative neoplasms (MPNs) were reported. However, data on patient-reported outcomes (PROs) in young adults with MPNs were rare.

Methods: We conducted a multicenter, cross-sectional study to compare the PROs in respondents with thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) by age at survey, including the young group (18-40 years), middle-aged group (41-60 years), and elderly group (>60 years).

Results: Of the 1,664 respondents with MPNs, 349 (21.0%) were young including 244 (69.9%) with ET, 34 (9.7%) with PV, and 71 (20.3%) with MF. In multivariate analyses, the young groups with ET and MF were associated with the lowest MPN-10 scores among the 3 age groups; those with MF, highest proportion of reporting negative impact of disease and therapy on their daily life and work. The young groups with MPNs had the highest physical component summary scores but the lowest mental component summary scores in those with ET. The young groups with MPNs were most concerned about fertility; those with ET, treatment-related adverse events and long-term efficacy of treatment.

Conclusions: We concluded that young adults with MPNs have different PROs compared with middle-aged and elderly patients.

查看原文本刊更多论文

年轻成人骨髓增生性肿瘤患者报告的预后。

本文报道了年轻成人骨髓增生性肿瘤(mpn)的遗传格局、疾病特征和临床结果。然而，关于年轻成年mpn患者报告结果(PROs)的数据很少。方法:我们进行了一项多中心、横切面研究，按调查年龄比较了血小板增多症(ET)、真性红细胞增多症(PV)和骨髓纤维化(MF)患者的pro，包括年轻组(18-40岁)、中年组(41-60岁)和老年组(60岁)。结果:1664例mpn患者中，349例(21.0%)为年轻人，其中ET 244例(69.9%)，PV 34例(9.7%)，MF 71例(20.3%)。在多变量分析中，3个年龄组中，有ET和MF的年轻组MPN-10得分最低;MF患者报告疾病和治疗对其日常生活和工作产生负面影响的比例最高。年轻mpn组身体成分总结得分最高，而ET组精神成分总结得分最低。年轻mpn组最关心生育问题;ET患者，治疗相关不良事件和治疗的长期疗效。结论:与中老年患者相比，青壮年mpn患者的PROs存在差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.